Pharmacy Times

NOVEMBER 14, 2023

Even with the current available treatment options, it is important to recognize the importance of masking, particularly for those with immunocompromised conditions.

Vaccines 101

Vaccines 101

Pharma Mirror

DECEMBER 1, 2021

Rockville, Emmes today announced that it conducted the data and statistical analysis for the third iteration of the Adaptive COVID-19 Treatment Trial (ACTT-3), using its proprietary Advantage eClinical system. The post Emmes Announces Completion of Third ACTT Clinical Trial for COVID-19 appeared first on Pharma Mirror Magazine.

Immunization 52

Immunization Hospitals 52

pharmaphorum

DECEMBER 22, 2020

Then COVID-19 hit, and organisations big and small were forced to pivot operations to tackle the real and present danger of the pandemic. The RECOVERY Trial, a multi-arm RCT studying the efficacy of several repurposed treatments in COVID-19, recruited a staggering 2,000-plus people across 16 NHS sites in little more than three weeks.

Vaccines 81

Vaccines 81

Outsourcing Pharma

JULY 23, 2020

The CRO has been tapped by the Frederick National Laboratory for Cancer Research to provide clinical services for an ongoing COVID-19 study.

61

61

Med Ed 101

MARCH 22, 2020

The world is a buzz with COVID-19 news and rightfully so. I want to cover hydroxychloroquine clinical pearls. The post Hydroxychloroquine Clinical Pearls – COVID-19 Buzz appeared first on Med Ed 101. This drug has been purported to have activity against coronavirus.

40

40

Pharma Mirror

MARCH 12, 2021

The leading Australian CRO for biotechs and Frost & Sullivan Asia-Pacific CRO Market Leadership Award winner Avance Clinical congratulated Atossa Therapeutics on the announcement of their Phase 1 final results for the AT-301 nasal spray being developed for COVID-19. Atossa Therapeutics, Inc.

52

52

European Pharmaceutical Review

MARCH 26, 2024

Moderna’s next-generation COVID-19 vaccine mRNA-1283 demonstrated a higher immune response against SARS-CoV-2, interim results from the company’s Phase III trial show. Moderna acknowledged that this patient population has the greatest risk for severe outcomes from COVID-19. Moderna’s Spikevax XBB.1.5-adapted

Vaccines 97

Vaccines Immunization 97

PhRMA

MARCH 21, 2023

The White House’s Office of Science and Technology Policy (OSTP) recently solicited stakeholder feedback on the clinical research infrastructure for emergency clinical trials, for which PhRMA submitted comments.

219

219

Hospital Pharmacy Europe

SEPTEMBER 25, 2023

The benefits of ensitrelvir use in patients with symptoms of long Covid and as a second-line treatment option for those hospitalised with Covid-19, have been presented at the recent European Scientific Working Group on Influenza and other Acute Respiratory Viruses’ (ESWI) Influenza Conference.

Hospitals 126

Hospitals FDA 126

Pharma Mirror

SEPTEMBER 22, 2021

A recent clinical study has shown that the ViroStop anti-viral spray from Swiss company, Herb-Pharma is effective in reducing the impact of Covid-19 for patients with mild to moderate symptoms. The volunteers.

40

40

Drug Topics

JANUARY 10, 2023

Researchers at Cleveland Clinic evaluated whether a bivalent COVID-19 vaccine protects against both strains of the virus - the original virus strain and a component of the omicron variant.

Vaccines 187

Vaccines 187

STAT

APRIL 26, 2024

The World Health Organization says new evidence shows the extensive overuse of antibiotics during the Covid-19 pandemic worldwide, which may have exacerbated “silent” spread of antimicrobial resistance. Overall, antibiotic use did not improve clinical outcomes for patients with Covid-19.

Specialty Pharmacies 73

Specialty Pharmacies Hospitals 73

Pharmacy Times

JUNE 28, 2022

At 1 month, a 50-µg booster dose of mRNA-1273.214 had a potent neutralizing antibody response against the Omicron variants in all individuals, regardless of prior infection.

123

123

Outsourcing Pharma

SEPTEMBER 28, 2021

Q BioMed reports it expects candidate MAN-19, intended to treat COVID-19-related Acute Respiratory Distress Syndrome, to enter trials early next year.

97

97

PhRMA

MARCH 27, 2023

It’s been over three years since I saw my first COVID-19 patient in the emergency department. A dramatic, and not all that common, clinical finding. The image of that x-ray is burned into my memory: clusters of white spots spread out across both sides of the patient’s lung.

Vaccines 214

Vaccines 214

Pharmaceutical Technology

MARCH 28, 2023

Following on from its Covid-19 vaccine programmes, BioNTech has set its sights on a range of infectious diseases for vaccine development. The company saw major successes with its Covid-19 vaccine, developed in collaboration with Pfizer. However, following its launch of the world’s first Omicron BA.4/BA.5

Vaccines 110

Vaccines 110

European Pharmaceutical Review

AUGUST 2, 2023

A new COVID-19 vaccine has been authorised by the Medicines and Healthcare products Regulatory Agency (MHRA). MHRA authorisation of Bimervax The COVID-19 vaccine, developed by HIPRA Human Health, combines a part of the SARS-CoV-2 virus spike protein with an adjuvant, according to the MHRA.

Vaccines 98

Vaccines Immunization 98

Pharmaceutical Technology

JUNE 20, 2023

The World Health Organisation (WHO) has granted an emergency use listing (EUL) to SK bioscience’s Covid-19 vaccine, SKYCovione. SKYCovione is a self-assembled nanoparticle vaccine and the 12th Covid-19 vaccine to receive a EUL from the regulator.

Vaccines 145

Vaccines Pharmaceutical Companies Pharmaceutical Companies 145

PharmExec

OCTOBER 26, 2023

A discussion of the biggest digital trends in clinical research, how COVID-19 impacted digital use for sponsors/CROs, what the future of DCT services looks like, and more.

105

105

pharmaphorum

FEBRUARY 21, 2022

The clinical research industry has long struggled with participant diversity. One study found that only 5% of Black or Asian United Kingdom residents had ever participated in a clinical trial. And then came COVID-19. And then came COVID-19. COVID-19 forced research organisations to adapt.

Vaccines 110

Vaccines FDA Hospitals 110

STAT

SEPTEMBER 11, 2023

The Food and Drug Administration announced Monday that it had greenlit two   updated Covid-19 booster shots in people as young as 6 months old, triggering a process that could see the Moderna and Pfizer-BioNTech vaccines become available in doctors’ offices, clinics, and pharmacies later this week.

Vaccines 145

Vaccines FDA 145

Pharmaceutical Technology

SEPTEMBER 19, 2022

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorisation for AstraZeneca ’s Evusheld (formerly AZD7442) for Covid-19 in the European Union (EU). These antibodies are obtained from B-cells of convalescent Covid-19 patients.

Dosage 111

Dosage Vaccines Immunization 111

Fierce Pharma

AUGUST 18, 2023

Thursday, Moderna presented preliminary data from a clinical trial of its updated mRNA shot, showing that it generates a robust response against currently circulating variants.

Vaccines 98

Vaccines 98

STAT

SEPTEMBER 14, 2023

Long Covid goes by  many names. Long Covid still looms as the national health disaster many predicted.  government rapidly anticipated and tried to blunt the force of this national calamity by investing in basic and clinical research. Although its prevalence has recently decreased to 6% of the U.S.

Patient Care 145

Patient Care 145

Pharmaceutical Technology

APRIL 10, 2023

The Malaysian Ministry of Health (MoH) has reportedly approved additional indication of Astrazeneca ’s Evusheld 100mg/ml solution for injection (Tixagevimab 100mg/ml and Cilgavimab 100mg/ml) for Covid-19 prevention. Dr Noor Hisham was quoted as saying: “The use of Evusheld was based on clinical guidelines issued by the health ministry.”

Vaccines 105

Vaccines Immunization 105

pharmaphorum

JANUARY 27, 2023

AstraZeneca’s revenue boost from COVID-19 therapy Evusheld looks set to be curbed early, as the FDA withdraws authorisation for the antibody on the grounds that it is ineffective against most subvariants now circulating in the US. which is now accounting for almost half of new cases of COVID-19.

FDA 135

FDA Chemotherapy Immunization Vaccines 135

Hospital Pharmacy Europe

APRIL 3, 2023

Nirmatrelvir treatment for patients with COVID-19 has been found to also reduce the risk of developing most post-COVID-19 condition symptoms US researchers from St Louis, Missouri have found that nirmatrelvir treatment during the acute phase of a COVID-19 infection, reduces the subsequent risk of developing post-COVID-19 condition or long covid.

Vaccines 96

Vaccines Hospitals 96

European Pharmaceutical Review

NOVEMBER 1, 2023

adapted COVID-19 vaccine, developed by Novavax for this autumn and winter season. is to be used for preventing COVID-19 in adults and children from 12 years of age. Approval of the only updated protein-based non-mRNA COVID-19 vaccine in the EU is an important milestone as the need for vaccination continues,” said John C.

Vaccines 102

Vaccines Immunization 102

Pharmaceutical Technology

JANUARY 26, 2023

Health Canada has accepted for review Valeo Pharma partner Veru’s new drug submission (NDS-CV) for Covid-19 therapy sabizabulin. In September last year, Valeo Pharma and Veru entered into a commercial services agreement in Canada for the agent as Covid-19 treatment. in deaths against placebo.

98

98

STAT

DECEMBER 12, 2022

to receive a Covid-19 vaccine outside of a clinical trial. A study released Tuesday by the Commonwealth Fund shows that in those two years, the Covid vaccines have averted over 3 million deaths in the U.S. This Wednesday will mark two years since nurse Sandra Lindsay became the first person in the U.S.

Vaccines 142

Vaccines Hospitals Immunization 142

Outsourcing Pharma

DECEMBER 7, 2020

A leader from data-centric CRO Quanticate shares perspective on how the pandemic has disrupted trials, and what tools and technologies can keep work going.

72

72

Outsourcing Pharma

FEBRUARY 16, 2021

A leader from the clinical data solutions firm explains how the challenges created by the pandemic have helped fuel creativity and innovation in studies.

67

67

Pharmaceutical Technology

DECEMBER 7, 2022

Health Canada has granted approval for a supplement to a New Drug Submission (sNDS) of Novavax ’s Covid-19 vaccine (Recombinant protein, Adjuvanted), Nuvaxovid (NVX-CoV2373), for use in adolescents aged 12 to 17 years. Effectiveness was backed by clinical efficacy showing that the vaccine offered an overall 79.5%

Vaccines 105

Vaccines Adverse Reactions 105

European Pharmaceutical Review

OCTOBER 20, 2022

Apogenix , a biopharmaceutical company developing next generation immunotherapeutics, announced that asunercept showed statistically significant benefits for hospitalised COVID-19 patients in the ASUNCTIS trial. It is being developed for the treatment of solid tumours, haematological malignancies and viral infections such as COVID-19.

Immunization 103

Immunization 103

Pharmaceutical Technology

MARCH 31, 2023

The European Medicines Agency (EMA) has recommended HIPRA’s Covid-19 vaccine , Bimervax, as a Covid-19 booster. It is expected to be as effective as Pfizer /BioNTech’s Comirnaty Covid-19 vaccine. The booster recommendation comes at a time when the future for Covid-19 vaccine rollouts is uncertain.

Vaccines 110

Vaccines Immunization 110

Pharmacy Times

SEPTEMBER 13, 2023

Senate Bill 219 will also allow pharmacists to independently administer influenza and COVID-19 tests waived by the clinical laboratory improvement amendments.

Vaccines 73

Vaccines 73

Pharmaceutical Technology

JULY 1, 2022

Pfizer has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) seeking approval for Paxlovid (nirmatrelvir tablets and ritonavir tablets) to treat Covid-19 patients at increased disease progression risk. An inhibitor of SARS-CoV-2 main protease (Mpro), Paxlovid is intended to be given orally.

FDA 105

FDA Vaccines 105